These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35323903)

  • 1. The impact of a csDMARD in combination with a TNF inhibitor on drug retention and clinical remission in axial spondyloarthritis.
    Nissen M; Delcoigne B; Di Giuseppe D; Jacobsson L; Hetland ML; Ciurea A; Nekvindova L; Iannone F; Akkoc N; Sokka-Isler T; Fagerli KM; Santos MJ; Codreanu C; Pombo-Suarez M; Rotar Z; Gudbjornsson B; van der Horst-Bruinsma I; Loft AG; Möller B; Mann H; Conti F; Yildirim Cetin G; Relas H; Michelsen B; Avila Ribeiro P; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Askling J; Glintborg B; Lindström U
    Rheumatology (Oxford); 2022 Nov; 61(12):4741-4751. PubMed ID: 35323903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.
    Ørnbjerg LM; Brahe CH; Askling J; Ciurea A; Mann H; Onen F; Kristianslund EK; Nordström D; Santos MJ; Codreanu C; Gómez-Reino J; Rotar Z; Gudbjornsson B; Di Giuseppe D; Nissen MJ; Pavelka K; Birlik M; Kvien T; Eklund KK; Barcelos A; Ionescu R; Sanchez-Piedra C; Tomsic M; Geirsson ÁJ; Loft AG; van der Horst-Bruinsma I; Jones G; Iannone F; Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Ann Rheum Dis; 2019 Nov; 78(11):1536-1544. PubMed ID: 31431486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients with psoriatic arthritis. Data from the EuroSpA collaboration.
    Lindström U; Di Giuseppe D; Delcoigne B; Glintborg B; Möller B; Ciurea A; Pombo-Suarez M; Sanchez-Piedra C; Eklund K; Relas H; Gudbjornsson B; Love TJ; Jones GT; Codreanu C; Ionescu R; Nekvindova L; Závada J; Atas N; Yolbas S; Fagerli KM; Michelsen B; Rotar Ž; Tomšič M; Iannone F; Santos MJ; Avila-Ribeiro P; Ørnbjerg LM; Østergaard M; Jacobsson LT; Askling J; Nissen MJ
    Ann Rheum Dis; 2021 Nov; 80(11):1410-1418. PubMed ID: 34083206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor inhibitor dose adaptation in psoriatic arthritis and axial spondyloarthritis (TAPAS): a retrospective cohort study.
    Michielsens CAJ; den Broeder N; Mulder MLM; van den Hoogen FHJ; Verhoef LM; den Broeder AA
    Rheumatology (Oxford); 2022 May; 61(6):2307-2315. PubMed ID: 34599803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.
    G S Saad C; S R Silva M; Sampaio-Barros PD; C B Moraes J; G Schainberg C; Gonçalves CR; Shimabuco AY; Aikawa NE; F N Yuki E; G Pasoto S; V K Kupa L; K Aoyama R; S R Araujo C; Silva CA; Medeiros-Ribeiro AC; Bonfa E
    Joint Bone Spine; 2023 Jan; 90(1):105464. PubMed ID: 36150668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey.
    Lopalco G; Venerito V; Cantarini L; Emmi G; Salaffi F; Di Carlo M; Tafuri S; Gentileschi S; Di Scala G; Nivuori M; Cacciapaglia F; Galeazzi M; Lapadula G; Iannone F
    Clin Exp Rheumatol; 2019; 37(5):762-767. PubMed ID: 31025925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration.
    Ørnbjerg LM; Linde L; Georgiadis S; Rasmussen SH; Lindström U; Askling J; Michelsen B; Giuseppe DD; Wallman JK; Pavelka K; Závada J; Nissen MJ; Jones GT; Relas H; Pirilä L; Tomšič M; Rotar Z; Geirsson AJ; Gudbjornsson B; Kristianslund EK; van Sder Horst-Bruinsma I; Loft AG; Laas K; Iannone F; Corrado A; Ciurea A; Santos MJ; Santos H; Codreanu C; Akkoc N; Gunduz OS; Glintborg B; Østergaard M; Hetland ML
    Semin Arthritis Rheum; 2022 Oct; 56():152081. PubMed ID: 35985172
    [TBL] [Abstract][Full Text] [Related]  

  • 8. One-Third of European Patients With Axial Spondyloarthritis Reach Pain Remission With Routine Care Tumor Necrosis Factor Inhibitor Treatment.
    Ørnbjerg LM; Rugbjerg K; Georgiadis S; Rasmussen SH; Lindström U; Pavelka K; Yilmaz N; Favalli EG; Nissen MJ; Michelsen B; Vieira-Sousa E; Jones GT; Ionescu R; Relas H; Sanchez-Piedra C; Tomšič M; Geirsson AJ; van der Horst-Bruinsma I; Askling J; Loft AG; Nekvindova L; Direskeneli H; Iannone F; Ciurea A; Fagerli KM; Santos MJ; Macfarlane GJ; Codreanu C; Eklund K; Pombo-Suarez M; Rotar Z; Gudbjornsson B; Rusman T; Østergaard M; Hetland ML
    J Rheumatol; 2023 Aug; 50(8):1009-1019. PubMed ID: 36455943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis and Predictors of 10-year Tumor Necrosis Factor Inhibitors Drug Survival in Patients with Spondyloarthritis: First-year Response Predicts Longterm Drug Persistence.
    Flouri ID; Markatseli TE; Boki KA; Papadopoulos I; Skopouli FN; Voulgari PV; Settas L; Zisopoulos D; Iliopoulos A; Geborek P; Drosos AA; Boumpas DT; Sidiropoulos P
    J Rheumatol; 2018 Jun; 45(6):785-794. PubMed ID: 29606666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct long-term disease activity trajectories differentiate early on treatment with etanercept in both rheumatoid arthritis and spondylarthritis patients: a prospective cohort study.
    Flouri I; Goutakoli P; Repa A; Bertsias A; Avgoustidis N; Eskitzis A; Pitsigavdaki S; Kalogiannaki E; Terizaki M; Bertsias G; Sidiropoulos P
    Rheumatol Int; 2024 Feb; 44(2):249-261. PubMed ID: 37815625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors associated with remission at 5-year follow-up in recent-onset axial spondyloarthritis: results from the DESIR cohort.
    Pina Vegas L; Sbidian E; Wendling D; Goupille P; Ferkal S; Le Corvoisier P; Ghaleh B; Luciani A; Claudepierre P
    Rheumatology (Oxford); 2022 Apr; 61(4):1487-1495. PubMed ID: 34270707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second and third TNF inhibitors in European patients with axial spondyloarthritis: effectiveness and impact of the reason for switching.
    Linde L; Ørnbjerg LM; Heegaard Brahe C; Wallman JK; Di Giuseppe D; Závada J; Castrejon I; Díaz-Gonzalez F; Rotar Z; Tomšič M; Glintborg B; Gudbjornsson B; Geirsson AJ; Michelsen B; Kristianslund EK; Santos MJ; Barcelos A; Nordström D; Eklund KK; Ciurea A; Nissen M; Akar S; Hejl Hyldstrup L; Krogh NS; Hetland ML; Østergaard M
    Rheumatology (Oxford); 2024 Jul; 63(7):1882-1892. PubMed ID: 37738257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High BMI is associated with lower TNF-α inhibitor serum trough levels and higher disease activity in patients with axial spondyloarthritis.
    de Wolff L; Arends S; Brouwer E; Bootsma H; Spoorenberg A
    Arthritis Res Ther; 2023 Oct; 25(1):202. PubMed ID: 37848964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting.
    Mease PJ; Accortt NA; Rebello S; Etzel CJ; Harrison RW; Aras GA; Gharaibeh MMF; Greenberg JD; Collier DH
    Rheumatol Int; 2019 Sep; 39(9):1547-1558. PubMed ID: 31321485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of comedication with conventional synthetic disease modifying antirheumatic drugs on TNF inhibitor drug survival in patients with ankylosing spondylitis and undifferentiated spondyloarthritis: results from a nationwide prospective study.
    Lie E; Kristensen LE; Forsblad-d'Elia H; Zverkova-Sandström T; Askling J; Jacobsson LT;
    Ann Rheum Dis; 2015 Jun; 74(6):970-8. PubMed ID: 25710471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Persistence of Methotrexate and Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    George MD; Baker JF; Ogdie A
    J Rheumatol; 2020 Jun; 47(6):826-834. PubMed ID: 31474599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of Tumor Necrosis Factor Inhibitors in Combination with Various csDMARD in the Treatment of Rheumatoid Arthritis: Data from the DREAM Registry.
    Manders SH; Kievit W; Jansen TL; Stolk JN; Visser H; Schilder AM; Vonkeman HE; Adang E; van de Laar MA; van Riel PL
    J Rheumatol; 2016 Oct; 43(10):1787-1794. PubMed ID: 27481900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort.
    Micheroli R; Tellenbach C; Scherer A; Bürki K; Niederman K; Nissen MJ; Zufferey P; Exer P; Möller B; Kyburz D; Ciurea A
    Ann Rheum Dis; 2020 Sep; 79(9):1203-1209. PubMed ID: 32581090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.